CAR T-cell therapy: Full speed ahead Conference Paper


Authors: Sermer, D.; Brentjens, R.
Title: CAR T-cell therapy: Full speed ahead
Conference Title: 15th International Conference on Malignant Lymphoma
Abstract: Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment for lymphoid malignancies, especially diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). However, there continue to be significant limitations of this therapy, such as incomplete or nonsustained responses and severe toxicities in a subset of patients. Furthermore, expanding the role of CAR T-cell therapy to new disease types is an important next step. In this review, we will highlight landmark trials for anti-CD19 CAR T cells and first-in-human trials of novel CARs, as well as discuss promising innovative CAR designs that are still undergoing preclinical development. Lastly, we will discuss toxicity and mechanisms of CAR T-cell resistance and failure, as well as potential future treatment approaches to these common issues. © 2019 John Wiley & Sons, Ltd.
Journal Title Hematological Oncology
Volume: 37
Issue: Suppl. 1
Conference Dates: 2019 Jun 18-22
Conference Location: Lugano, Switzerland
ISBN: 0278-0232
Publisher: Wiley Blackwell  
Date Published: 2019-04-01
Start Page: 95
End Page: 100
Language: English
DOI: 10.1002/hon.2591
PUBMED: 31187533
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Renier J Brentjens
    282 Brentjens
  2. David Sermer
    12 Sermer